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VitagenesOxidative stress has been suggested to play a main role in the pathogenesis of type 2 diabetes mellitus and its
complications. As a consequence of this increased oxidative status a cellular adaptive response occurs requiring
functional chaperones, antioxidant production and protein degradation. This studywas designed to evaluate sys-
temic oxidative stress and cellular stress response in patients suffering from type 2 diabetes and in age-matched
healthy subjects. Systemic oxidative stress has been evaluated by measuring plasma reduced and oxidized glu-
tathione, as well as pentosidine, protein carbonyls lipid oxidation products 4-hydroxy-2-nonenal and F2-
isoprostanes in plasma, and lymphocytes, whereas the lymphocyte levels of the heat shock proteins (HSP)
HO-1, Hsp72, Sirtuin-1, Sirtuin-2 and thioredoxin reductase-1 (TrxR-1) have beenmeasured to evaluate the sys-
temic cellular stress response. PlasmaGSH/GSSG showed a signiﬁcant decrease in type 2 diabetes as compared to
control group, associated with increased pentosidine, F2-isoprostanes, carbonyls and HNE levels. In addition,
lymphocyte levels of HO-1, Hsp70, Trx and TrxR-1 (Pb0.05 and Pb0.01) in diabetic patients were higher than
in normal subjects, while sirtuin-1 and sirtuin-2 proteinwas signiﬁcantly decreased (pb0.05). In conclusion, pa-
tients affected by type 2 diabetes are under condition of systemic oxidative stress and, although the relevance of
downregulation in sirtuin signal has to be fully understood, however induction of HSPs and thioredoxin protein
system represent a maintained response in counteracting systemic pro-oxidant status. This article is part of a
Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Oxidative stress is caused by an unbalance between a relative
overload of oxidants and a depletion of antioxidants, and it is impli-
cated in the pathogenesis of several chronic diseases, including ath-
erosclerosis, ischaemia/reperfusion injury, chronic inﬂammatory
diseases, renal failure and diabetes mellitus [1–4]. As a consequence
of the increased burden of oxidative stress severe damage to DNA,
proteins and lipids occur [1]. With regard to the role of oxidative
stress in the pathogenesis and in the clinical history of diabetes mel-
litus, compelling evidences have been provided that both Type 1 and
Type 2 diabetic patients are under conditions of an increased oxida-
tive stress and that the complications of diabetes mellitus are partially
mediated by oxidative stress [4–6]. Several mechanisms seem to beants and Antioxidant Treatment
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rights reserved.involved in the genesis of oxidative stress in diabetic patients.
Among these, glucose autoxidation, non enzymatic protein glyca-
tion as well as the formation of advanced-glycation end-products
(AGEs) have been demonstrated in patients with diabetes and a di-
rect relationship with the circulating blood glucose levels and glu-
cose variability has been repeatedly demonstrated [5,7,8]. In
particular, it has been shown that two subclasses of AGEs, such as
N-ε(carboxymethyl)lysine and pentosidine, accumulate in various
tissues of poorly controlled diabetic patients [9]. The interplay be-
tween oxidative stress and AGEs is very complex. In fact, reactive
oxygen species (ROS) accelerate the formation of AGEs, which in
turn, as glycated proteins, are also able to produce ROS via complex
biochemical mechanisms [10–12]. During these reactions, protein
modiﬁcations take place and compounds with a carbonyl or dicarbo-
nyl moieties are formed [5].
In addition to the above mentioned AGEs and protein carbonyls,
various other products derived from lipid peroxidation accumulate
in biological ﬂuids and tissues of diabetic patients. 4-hydroxy-2-
nonenal (HNE) is considered an important marker of lipid peroxida-
tion, but at the same time it is directly involved in both citotoxicity
and mutagenic activity. In fact, 4-HNE further reacts with protein
Table 1
Clinical parameters of diabetic patients with normal renal function.
Clinical parameters (unit) Mean±SEM (range)
Age (years) 61±4 (35–71)
Male/female 8/7
Body weight (Kg) 82±17 (65–94)
Height (cm) 165±10 (152–175)
Body mass index 28±7 (24–34)
Plasma creatinine (mg/dl) 1,04±0.52 (0.84–1.37)
Creatinine clearance (ml/min) 76±10 (66–96)
MDRD-estimated GFR (ml/min) 74±6 (59–89)
24 h proteinuria (mg) 77±16 (44–249)
Fasting plasma glucose (mg/dl) 133±12 (120–243)
Glycated hemoglobin (%) 6.4±2.2 (4.6–9.7)
Sistolic blood pressure (mm Hg) 155±10 (140–165)
Diastolic blood pressure (mm Hg) 85±6 (70–95)
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Interestingly, HNE-modiﬁed proteins have been identiﬁed in the
serum and in renal tissues of type 2 diabetic patients [13,15]. The
free radical-based oxidation of arachidonic acid [16,17] is one of the
most relevant biochemical pathways that generate isoprostanes. In-
creased levels of F2-isoprostanes can be found in the plasma or
urine of patients affected by several chronic inﬂammatory or degen-
erative diseases, including diabetes, and are currently used as in
vivo indicators of lipid peroxidation [5,18–21]. It is of interest that
in addition to their well known role as in indicator of the oxidative
stress status, several lines of evidences demonstrate that F2-
isoprostanes are directly involved in vascular function and endotheli-
al mediated platelet aggregation [22–24].
In order to adapt to environmental changes and survive to differ-
ent types of injuries, eukaryotic cells have developed a complex net-
works of cellular stress response mechanisms which detect and
control different forms of stress. These responses include the heat
shock protein synthesis [25–29] as well as the stimulation of the
thioredoxin system [30,31]. Together, they form a powerful system
involved in many intracellular and extracellular processes, including
cell proliferation, the redox regulation of gene expression and signal
transduction, protection against oxidative stress, anti-apoptotic func-
tions, growth factor and cytokine-like effects, and the regulation of
the redox state of the extracellular environment [27]. The nicotin-
amide adenine dinucleotide (NAD)-dependent deacetylase, named
sirtuin, are a complex of proteins that modulate the transcriptional si-
lencing of selected region of the genome via the regulation of pro-
teins' acetylation–deacetylation pathways. They play a signiﬁcant
role in the aging @@process and in the pathogenesis of various chron-
ic and degenerative diseases [32]. The present study was designed to
evaluate the presence of systemic oxidative stress, glutathione status
and cellular stress response in plasma and lymphocytes of patients
with type 2 diabetes. Furthermore, we demonstrated in the same pa-
tients, for the ﬁrst time in literature to our knowledge, that changes
in the redox state of glutathione are associated with activation of
cellular stress response, evaluated as the induction at the circulating
lymphocyte level of heme oxygenase-1, Hsp70 as well as the anti-
oxidant thioredoxin protein and the related enzyme thioredoxin
reductase-1 (TrxR-1) and with a signiﬁcant reduction of Sirtuin
expression.2. Methods
2.1. Patients
All the procedures on human subjects have been conducted in ac-
cordance with the guidelines in the Declaration of Helsinki and the
experimental protocol has been formally approved by the Ethical
Committee of the University of Catania. All the patients gave also
their informed consent prior to undergo any procedure. Fifteen adults
with type 2 diabetes which were followed on a regular basis in the
outpatient clinic of the Department of Internal Medicine of the Policli-
nico di Catania joined this study. Clinical data of the participating sub-
jects are summarized in Table 1. Patients were referred by the
primary care physicians or by one of the outpatient Diabetes Centers
of the Catania metropolitan area. Exclusion criteria were the follow-
ing: renal insufﬁciency secondary to diabetes or to any other cause,
ischemic heart disease or heart failure (stage 2 or above according
to NYHA classiﬁcation), hepatic failure, endocrine disease other than
diabetes mellitus, any other clinical or laboratory evidence of major
organ disease. All patients underwent to a run in period of 4 to
8 weeks designed to achieve a stabilization of blood pressure levels,
blood glucose control. All the subjects were not taking antioxi-
dants, no limitation was given to the type of pharmacological
therapy employed to control diabetes or hypertension,medications were maintained constant throughout the entire du-
ration of the study.2.2. Samples
Blood (6 ml) was collected after an overnight fast by venopunc-
ture from an antecubital vein in EDTA-coated tubes. Immediately
after sampling, 2 ml of blood were centrifuged at 10,000×g for
1 min at 4 °C to separate plasma from red blood cells and 4 ml were
utilized for lymphocytes puriﬁcation.2.3. Lymphocytes puriﬁcation
Lymphocytes from peripheral blood were puriﬁed by using the
Ficoll Paque System following the procedure provided by the manu-
facturer (GE Healthcare, Piscataway, NJ).2.4. Reduced and oxidized glutathione assay
Reduced glutathione (GSH) and glutathione disulﬁde (GSSG) were
measured by the NADPH-dependent GSSG reductase method as de-
scribed by Adams et al. [33]. For total glutathione (GSH+GSSG), ali-
quots (0.1 ml) of whole blood were immediately added to 0.1 ml of
a cold solution containing 10 mM DTNB and 5 mM EDTA in 100 mM
potassium phosphate, pH 7.5. The sample were mixed by tilting and
centrifuged at 12,000 g for 2 min at 4 °C. An aliquot (50 μl) of the su-
pernatant was added to a cuvette containing 0.5 U of GSSG reductase
in 100 mM potassium phosphate and 5 mM EDTA, pH 7.5 (buffer 1).
After 1 min of equilibration, the reaction was initiated with
220 nmol of NADPH in buffer 1 for a ﬁnal reaction volume of 1 ml.
The formation of a GSH-DTNB conjugate was then measured at
λ=412 nm. The reference cuvette contained equal concentrations
of DTNB, NADPH and enzyme, but not sample. For the GSSG assay, al-
iquot (0.75 ml) of blood samples were immediately added to 0.75 ml
of a solution containing 10 mM NEM and 5 mM EDTA in 100 mM po-
tassium phosphate, pH 7.5. The sample were mixed by tilting and
centrifuged at 12,000 g for 2 min at 4 °C. An aliquot (900 μl) of the su-
pernatant was passed at one drop/s through a SEP-PAK C18 Column
(Waters, Framingham, MA) that had been washed with methanol fol-
lowed by water. The column was then washed with 0.1 ml of buffer 1.
Aliquots (865 μl) of the combined eluates were added to a cuvette
with 250 nmol of DTNB and 0.5 U of GSSG reductase. The assay then
proceeded as in the measurement of total GSH. GSH was then
obtained by subtracting GSSG values from total glutathione. GSH
and GSSG standards in the ranges between 0 and 10 nmol and 0.010
and 10 nmol, respectively, added to control samples were used to
Fig. 1. Plasma levels of reduced (GSH) and oxidized (GSSG) glutathione in type 2 Diabetic
Patients and Controls. Plasma GSH and GSSG contents were assayed as described in
Methods. Data are expressed asmean±SEMof 15 patients per group. *Pb0.05 vs controls.
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nmol of GSH or GSSG, respectively, per ml of blood.
2.5. Western blot analysis
Plasma samples were ready to use, while the lymphocyte pellet
was homogenized and centrifuged at 10,000×g for 10 min and the
supernatant was used for analysis after dosage of proteins. The Ali-
quot (40 μg) of protein extract was separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), transferred over-
night to nitrocellulose membrane and the non speciﬁc binding of an-
tibodies was blocked with 3% non-fat dry milk in PBS. Membrane
were then probed with a monoclonal mouse anti-Hsp70 antibody
(SPA-810, Stressgen, Ann Arbor, MI, USA) that recognizes only the in-
ducible form, while immunodetection of HO-1, DNPH, HNE, Trx, TrxR-
1, Sirt-1 and Sirt-2 was performed using polyclonal rabbit antibodies:
SPA-895 (Stressgen), V0401 (DAKO, Glostrup, Denmark), HNE11-S
(Alpha Diagnostic International, San Antonio, TX, USA), 07–613 (Up-
state Biotechnology, Charlottesville, VA), sc-15404 and sc-20966
(Santa Cruz Biotech. Inc., Santa Cruz, CA,USA), respectively. A goat
polyclonal antibody speciﬁc for β-actin was used for loading control
(1:1000). Blots were then incubated with secondary horseradish per-
oxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (IgG)
when probing DNPH, HNE, Trx, TrxR-1, sirtuin-1 and sirtuin-2,
whereas a HRP-conjugated goat anti-mouse (IgG) was used in the
case of Hsp70 and HRP-conjugated anti-goat (IgG) for detection of
β-actin followed by ECL chemiluminescence (Amersham, GE Health-
care, Piscataway, NJ). Immunoreactive bands were quantiﬁed by
scanning Western blot imaged ﬁlms with a laser densitometer (LKB-
Ultrascan, XL model, Pharmacia, American Instruments, Haverhill,
MA, USA).
2.6. Measurement of F2-isoprostanes and pentosidine
The HPLC analysis of F2-isoprostanes was performed as described
by Ritov et al. [34]. Values are expressed as nM for plasma F2-
isoprostanes. Plasma pentosidine was measured according to Miyata
et al. [35]. Values are expressed as pmol/mg protein.
2.7. Protein measurements
Sample protein concentrationswere determined by the bicinchoninic
acid (BCA) method [36].
2.8. Statistical analysis
All results are expressed as means±S.E.M. Each experiment was
performed, unless otherwise speciﬁed, in triplicate. Data were ana-
lyzed by one-way ANOVA, followed by inspection of all differences
by Duncan's new multiple-range test. Differences were considered
signiﬁcant at Pb0.05.
3. Results
Diabetes is a chronic inﬂammatory disease and this study was
designed to evaluate systemic oxidative stress and cellular stress re-
sponse in patients suffering from type 2 diabetes and in age-
matched healthy subjects. Clinical data of patients and control sub-
jects are summarized in Table 1.
The content of reduced and oxidized GSH in plasma of type 2 dia-
betic patients was determined as a measure of the antioxidant status
and compared with the levels in the control group (Fig. 1). We found
a signiﬁcant decrease (to 63% of control levels) in the content of re-
duced GSH and a signiﬁcant increase (by 46%) in the content of oxi-
dized GSH (GSSG) in the diabetic samples compared with the
control samples. These changes in absolute GSH and GSSGconcentrations resulted in a 68% decrease in the GSH/GSSG ratio in
type 2 diabetes compared with control patients (data not shown).
Changes in the redox glutathione status were consistent with oxida-
tive modiﬁcations of redox status in plasma proteins between the ex-
perimental and control groups investigated. Protein oxidation was
evaluated by measuring the amount of protein carbonyls (DNPH).
Protein carbonyls most often are detected by two methods, i.e., deriv-
atization with 2,4-dinitrophenylhydrazine (DNPH), followed by im-
munochemical detection with an antibody against the resulting
protein hydrazone, or formation of the Schiff base by biotin hydrazide
followed by detection of the protein-bound imine with enzyme- or
ﬂuorophore-linked avidin or streptavidin. Here we describe the
DNPH-based detection method that is routinely used for detection
of carbonylated proteins. In the DNPH method, samples are deriva-
tized with DNPH. DNPH reacts with carbonyl groups to form
protein-resident 2,4-dinitrophenylhydrazone (DNP), which is then
detected using commercially available anti-DNP antibodies. As
shown in Fig. 2A, protein carbonyls were found at a signiﬁcantly
(pb0.05) higher level in plasma of type 2 diabetic patients than in
control subjects. Furthermore, one measure of oxidative marker is
lipid oxidation, indexed by HNE, which can also occur in brain and pe-
ripheral tissues under oxidative stress [37,38]. HNE, formed from ara-
chidonic acid or other unsaturated fatty acids following free radical
attack, was bound by Michael in addition to proteins, particularly at
cysteine, histidine, or lysine residues [39]. Examination of plasma
content of HNE in diabetic patients showed a signiﬁcant (pb0.05) el-
evation of protein-bound HNE as compared to control group (Fig. 2B).
As previously reported, AGEs, such as pentosidine, are reliable
markers of oxidative stress in diabetes and diabetic nephropathy,
but they can trigger per se further inﬂammation thus creating a self-
sustained vicious circle responsible for tissue damage [38,40]. In ac-
cordance with this theory, we demonstrated a signiﬁcant increase
(Pb0.01) in plasma levels (Fig. 3A) of pentosidine in patients suffer-
ing from type 2 diabetes with respect to control subjects. The next
Fig. 2. Protein carbonyls and 4-hydroxy-2-nonenals levels in plasma from type 2 diabetic patients. Plasma samples from type 2 diabetic patients and age-matched controls were
assayed for protein carbonyls (DNPH) (Fig. 2A) and 4-hydroxy-2-nonenals (HNE) (Fig. 2B) by western blot as described in Methods. Representative immunoblots are shown
(Fig. 2C) and (Fig. 2D). The bar graph shows the densitometric evaluation and values are expressed as mean±SEM of 15 patients per group.
732 V. Calabrese et al. / Biochimica et Biophysica Acta 1822 (2012) 729–736step was to evaluate the effects of observed systemic pro-oxidant
conditions on lipids-derived circulating F2 isoprostanes. As shown
in Fig. 3B, a signiﬁcant elevation (Pb0.05) of in plasma levels of
total F2-isoprostanes has been found in type 2 diabetic patients
(Pb0.01) with respect to controls.
The heat shock response contributes to establishing a cytoprotec-
tive state in a wide variety of human diseases, including inﬂamma-
tion, cancer, aging and neurodegenerative disorders. The vitagene
family is composed of the heat shock proteins HO-1 (also called
Hsp32), Hsp70, by the thioredoxin system and by sirtuin proteins
[41,42]. We therefore evaluated the expression levels of cellular stress
response proteins in plasma and lymphocytes in control and type 2
diabetes patients. Western blot analysis of plasma probed for thiore-
doxin (Trx) antioxidant protein expression is reported in Fig. 4. Trx
expression was signiﬁcantly (pb0.05) decreased in the plasma of di-
abetic patients, compared to controls.
Heme oxygenase-1 (HO-1), also referred to as Hsp32, belongs to
the Hsp family and protects brain cells from oxidative stress by
degrading toxic heme into free iron, carbon monoxide and biliverdin
[29,43,44]. This latter is then reduced by biliverdin reductase (BVR)
into bilirubin (BR), a linear tetrapyrrole with antioxidant properties;
very recently, BR has been shown to effectively counteract also nitro-
sative stress, due to its ability to bind and inactivate NO and RNS
[43,45,46]. We evaluated the expression of inducible HO-1 isoform
in lymphocytes of type 2 diabetes patients and in controls. As
shown in Fig. 5, HO-1 protein expression was higher in samples
from diabetes patients compared to controls.
The 70 kDa family of stress proteins is one of the most extensively
studied cytoprotective system which includes the constitutive heat
shock cognate isoform (Hsc70), and the inducible isoform, Hsp70(also referred to as Hsp72). Here we evaluated the inducible isoform
and its expression is reported in Fig. 6A, which shows a signiﬁcant
(pb0.05) increase in type 2 diabetes lymphocytes with respect to
healthy control subjects. A representative immunoblot is also shown
(Fig. 6B).
Analysis of lymphocytes in type 2 diabetes patients, compared to
control group, revealed also a signiﬁcant (pb0.05) reduction of Trx
expression (Fig. 7) which was associated with increased levels of
the enzyme Thioredoxin reductase-1 (Fig. 8). Interestingly, we
found a signiﬁcant (pb0.05) decrease in the levels of sirtuin-1 as
well as sirtuin-2 proteins in lymphocytes of diabetic patients than in
control group (Fig. 9A,C and Fig. 9 B,D). As far as we are concerned
this is the ﬁrst evidence of changes in sirtuin-1 and sirtuin-2 expres-
sion in type 2 diabetes, although at the moment we can not exclude
that this might not be a speciﬁc alteration of this progressive chronic
inﬂammatory systemic disease.
4. Discussion
Prevalence of diabetes is constantly increasing in the United
States, in Europe as well as in developing countries and the global
burden associated with the disease is becoming one of the most rele-
vant world health problem [47]. The long term exposure to chronic
hyperglycaemia along with the increase in oxidative stress that char-
acterizes the diabetic patients results in the formation and accumula-
tion of AGEs [4,7,9,48,49]. AGEs have a wide range of chemical,
cellular, and tissue effects that contribute to the development of
chronic complication of diabetes [40,50]. The importance of AGEs as
downstream mediators of tissue injury in diabetes has been demon-
strated by animal studies in which the inhibition of the advanced
Fig. 5. Heme oxygenase-1 levels in lymphocytes from type 2 diabetic patients. Lymphocyte
samples frompatientswith nephropathy secondary to type 2 diabetes and age-matched con-
trols were assayed for heme oxygenase-1 (HO-1) bywestern blot as described inMethods. A
representative immunoblot is shown.β-actin has been used as loading control. The bar graph
shows the densitometric evaluation and values are expressed asmean±SEMof independent
analyses on 15 patients per group. *Pb0.05 vs control. D.U., densitometric units.
Fig. 3. Pentosidine and Total F2-isoprostanes levels in plasma from type 2 diabetic patients.
Plasma samples from patients with type 2 diabetes and age-matched controls were assayed
for pentosidine (Fig. 3A) and total F2-isoprostanes (Fig. 3B) as indicated in Methods. Data
are expressed as mean±SEM of 15 patients per group. *Pb0.01 vs controls.
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cations without any direct effect on the glycemic control [40]. Fur-
thermore, AGEs-modiﬁed proteins undergo physico-chemical
changes which alter charge, solubility and conformation resulting in
an altered protein [40]. Finally, the effects of AGEs, together with
hyperglycaemia and ROS induce growth factors and cytokines causing
organ hypertrophy, as the enlarged kidneys in diabetic nephropathy
and accumulation of extracellular matrix components [50]. Our re-
sults showing an elevation in plasma AGEs in patients with diabetes
compared with healthy subjects are in accordance with current liter-
ature [51–53].Fig. 4. Plasma levels of Thioredoxin in type 2 diabetes and controls subjects. Plasma samples
from patients with nephropathy secondary to type 2 diabetes and age-matched controls
were assayed for thioredoxin (Trx) bywestern blot as described inMethods. A representative
immunoblot is shown. β-actin has been used as loading control. The bar graphs show the
densitometric evaluation and values are expressed as mean±SEM of 15 patients per
group. *Pb0.05 vs control. D.U., densitometric units.Reactive carbonyl compounds, which are known precursors of car-
bonyl stress, can be generated during the AGEs-mediated free radical
formation [54,55]. Our evidence of an increased levels of carbonyls
both in plasma and lymphocytes from type 2 diabetic patients are in
line with clinical and experimental data showing an increased gener-
ation of ROS in diabetes [5,56,57]. 4-hydroxy-2-nonenal (HNE) are
formed from arachidonic acid or other unsaturated fatty acids follow-
ing free radical attack and bind, by Michael addition, to proteins par-
ticularly at cysteine, hystidine, or lysine residues [14,37]. Thus,
protein-bound HNE is a reliable index of lipid oxidative stress which
can also occur in different organs under oxidative stress conditions
[13,15,54,58]. Isoprostanes are derived by the free radical-catalyzed
peroxidation of arachidonic acid, they are formed in situ from phos-
pholipids and subsequently released in the circulation by a phospho-
lipase and eventually excreted in urine [16,59]. Isoprostanes, in
contrast to lipid hydroperoxides, are chemically stable end products
of lipid peroxidation, and the measurement of their levels in plasma
or urine may permit a sensitive and speciﬁc method for detection of
lipid oxidative damage in vivo [19]. Their concentration in the urine
is one of the most readily available index of lipid oxidation and,
more in general, of the oxidative stress status of a patient population.
The F2-isoprostane levels in type 2 diabetic patients are consitently in-
creased [18,60,61]. In a previous study we demonstrated an increased
level of F2 isoprostanes in type 2 diabetic patients with incipient diabetic
nephropathy [38]. Our results show a signiﬁcant increase in both plasmaFig. 6. Heat shock protein 70 levels in lymphocytes from type 2 diabetic patients. Lym-
phocyte samples from patients with nephropathy secondary to type 2 diabetes and
age-matched controls were assayed for heat shock protein 70 (Hsp70) by western
blot as described in Materials and Methods. A representative immunoblot is shown. β-
actin has been used as loading control. The bar graph shows the densitometric evaluation
and values are expressed as mean±SEM of independent analyses on 15 patients per
group. *Pb0.05 vs control. D.U., densitometric units.
Fig. 7. Thioredoxin levels in lymphocytes from diabetic nephropathic patients. Lym-
phocyte samples from patients with nephropathy secondary to type 2 diabetes and
age-matched controls were assayed for thioredoxin (Trx) by western blot as described
in Methods. A representative immunoblot is shown. β-actin has been used as loading
control. The bar graphs show the densitometric evaluation and values are expressed
as mean±SEM of independent analyses on 15 patients per group. *Pb0.05 vs control.
D.U., densitometric units.
Fig. 9. Levels of sirtuin-1 (Fig. 9A) and sirtuin-2 (Fig. 9B) in lymphocytes from type 2 diabetic
patients. Blood sampleswere assayed for sirtuins (Sirt-1, Sirt-2) byWestern blot as described
inMethods. Representative immunoblots are shown inC and respectivelyD.β-actinhas been
used as loading control. The bar graph shows the densitometric evaluation and values are
expressed as mean standard error of mean of independent analyses on 15 patients per
group. P≤0.05 vs control. D.U., densitometric units.
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a condition of systemic rather than local pro-oxidant status. In recent
years, it was also shown that isoprostane directly affects platelet aggre-
gation and may therefore be implicated in macrovascular complication
of diabetes [24].
Eucariotic cells have developed various pathways to counteract
oxidative stress-related damage. Among these stress, induced pro-
teins, chaperones are essential to help the correct folding and mainte-
nance of the proper conformation of other proteins and to promote
cell survival after a large variety of environmental stresses. Therefore,
normal chaperone function plays a pivotal role in the endogenous re-
sponse of several tissues to an increased cellular stress, whereas al-
tered chaperone function has been associated with the development
of several diseases [27,62]. To this regard, the expression of HO-1,
Hsp70, as well as of TrxR-1 in peripheral lymphocytes of patients
with type 2 diabetes is signiﬁcantly increased. Consistent to this, we
show that type 2 diabetes is associated with signiﬁcant perturbation
of systemic redox state, as revealed by a signiﬁcant decrease in both
reduced glutathione and thioredoxin protein. Hsp70 induction has
been proved to be an efﬁcient system helping the recovery from aFig. 8. Thioredoxin reductase-1 levels in lymphocytes from diabetic nephropathic patients.
Lymphocyte samples from patients with nephropathy secondary to type 2 diabetes and
age-matched controls were assayed for thioredoxin reductase-1 (TrxR-1) by western blot
as described in Materials and Methods. A representative immunoblot is shown. β-actin
has been used as loading control. The bar graphs show the densitometric evaluation and
values are expressed as mean±SEM of independent analyses on 15 patients per group.
*Pb0.05 vs control. D.U., densitometric units.large number of diseases, such as atherosclerotic and inﬂammatory
disease, diabetes and neurodegenerative damage-associated patholo-
gies [25–27,62,63]. The physiological response of HO-1 protein in
human lymphocytes is also intriguing. Under oxidative stress condi-
tions, HO-1 is one of the early genes to be induced and it exerts cyto-
protective functions by inducing the metabolic pathway of pro-
oxidant heme degradation and the production of both the vasoactive
molecule carbon monoxide and biliverdin, the latter being the pre-
cursor of the powerful antioxidant and antinitrosative molecule bili-
rubin [27,62,64]. Thus, HO-1 increase in the lymphocytes of patients
with type 2 diabetes suggests that, in response to an oxidant insult,
induction of an early gene is a signiﬁcant part of the antioxidant re-
sponse and this is much more interesting considering the long term
course of a disease such as diabetes. The thioredoxin system (thiore-
doxin, thioredoxin reductase, and NADPH) regulates cellular redox
balance through the reversible oxidization of its redox-active cysteine
residues (−Cys-Gly-Pro-Cys-) to form a disulﬁde bond that in turn is
reduced by thioredoxin reductase and NADPH [30,31,65]. Thioredoxin
plays an essential role in cell function by limiting oxidative stress directly
via antioxidant effects and indirectly by protein–protein interactions
735V. Calabrese et al. / Biochimica et Biophysica Acta 1822 (2012) 729–736with key signaling molecules, such as the thioredoxin-interacting pro-
tein [66]. We have shown an increased TrxR protein expression in lym-
phocytes of diabetic patients which is in agreement with the well
known effects induced by oxidative stress [67]. Our study provides evi-
dence also that sirtuin signal is downregulated in type 2 diabetes respect
to healthy control subjects. This is consistent with the recent notion that
sirtuins reduce reactive oxygen species formation by modulating the
acetylation of the respiratory chain and by stimulating mithocondria su-
peroxide dismutase (SOD-2) and isocitrate dehydrogenasewhich gener-
ates NADPH for the glutathione pathway. Thus, changes in sirtuin
expression, as observed in our study, may contribute to explain the fail-
ure in diabetic defense mechanisms against sustained oxidative stress
[32]. Furthermore, given the interplay between reactive oxygen species
and insulin signal transduction, it is of interest that while small physio-
logic amount of H2O2 mimic the action of insulin and stimulate glucose
uptake, in contrast, a large body of clinical evidence shows that sustained
oxidative stress correlates directly with both mean blood glucose levels,
as well as glucose variability, in response to anti-diabetic therapy [68].
Consistently, it is known that glucose and lipid levels can exert a direct
toxic effect on beta cell function and insulin secretion. A direct role of
oxidative stress and AGE on insulin secretion has been demonstrated
in vivo, however, few data are available in vivo on a potentially advanta-
geous effects of anti oxidative therapies on beta cell function in dia-
betics. Data on an early positive effect anti oxidant administration on
insulin secretion of patientswith a family history of diabeteswould sug-
gest the need of an early intervention prior that irreversible loss of beta
cell mass and function have occurred [68].
The above discussed data demonstrate the role of oxidative and
glycoxidative pathways in diabetes and unravel the importance of
systemic cellular stress response mechanisms, in particular vitagenes
which, if stimulated, may counteract this pro-oxidant status. It is
plausible to hypothesize that novel therapeutic approaches, based
on combined nutritional and pharmacologic interventions, can be
designed to burst cellular stress response as a mean to control and
reduce oxidative stress-mediated formation of AGEs as well as to
remove AGE-induced modiﬁcations, thus constituting an impor-
tant component of future prophylaxis and therapy in patients with
diabetes.
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